부산대학교 도서관

This article explores the challenges that arise in pretransfusion testing and blood typing due to the use of monoclonal antibody cancer therapies, specifically focusing on magrolimab (Hu5F9-G4). The therapy interferes with CD47, a protein expressed on cancer cells as well as red blood cells and platelets, which can lead to false-positive results in serological tests and difficulties in providing compatible blood for transfusions. The article also discusses the interference caused by another monoclonal antibody therapy, anti-CD38, and provides strategies to mitigate these issues. The article emphasizes the importance of effective communication and provides recommendations for managing the interference caused by magrolimab in clinical trials. [Extracted from the article]